- CEO
- Yong Li Wang
- Full Time Employees
- 998
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Kuang Yi Building Beijing BE China 100191
- IPO Date
- Oct 21, 2014
- Business
- Beijing Strong Biotechnologies, Inc. (300406.SZ) researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services primarily in China and internationally. Founded in 2001 and headquartered in Beijing, China, the company offers a comprehensive portfolio of clinical biochemistry reagents covering liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, therapeutic drug monitoring (TDM), and other panels using enzymatic, immunoturbidimetric, latex immunoturbidimetric, CEDIA, and EMIT methods; coagulation reagents including routine and special items under the Beijing MDC brand; blood grouping cards and systems utilizing DG Gel card technology launched in 2018; and instruments such as automated coagulation analyzers, automatic biochemistry analyzers, automated blood grouping analyzers, and fully automatic chemiluminescence immunoassay analyzers. It operates through brands GCELL for biochemistry and blood typing, and Beijing MDC for coagulation, serving hospitals, pharmaceuticals, and institutions with a nationwide sales network in China and global marketing channels, while maintaining strategic partnerships with Abbott, Roche, Hitachi, Mindray, and Weigao. Recent developments include the acquisition of Beijing MDC in 2017 to expand its coagulation testing product line, the purchase of 65.55% of Maixin Biotech in 2020 with a potential full acquisition of remaining shares announced in 2021 to enhance tumor pathology diagnostics, multiple new reagent approvals such as N-terminal pro-brain natriuretic peptide kits and digoxin assay kits from Beijing regulators in 2024-2025, six biochemistry kits gaining TÜV Rheinland IVDR certification, and completion of a shareholding increase by China National Pharmaceutical Investment totaling 4.34 million shares in December 2024.